Does Short-Term Low-Dose Methotrexate Treatment Affect Homocysteine Blood Level in Patients with Psoriasis?

Authors

  • Malekzad Farhad
  • Nasiri Soheila
  • Qeisari Mehdi
  • Rahmati-Roudsari Mohammad
  • Saeedi Marjan
  • Sarlak Mojdeh
Abstract:

Background: An elevated homocysteine level is an independent risk factor for cardiovascular disorders. Psoriatic patients have an increased risk of cardiovascular diseases; In addition, hyperhomocysteinemia is a complication of methotrexate treatment. We undertook a study to evaluate the plasma levels of homocysteine, vitamin B12 and folate in patients with psoriasis before and after short-term low-dose methotrexate treatment. Methods: Twenty six patients with psoriasis were recruited. The plasma levels of homocysteine, vitamin B12 and folate were evaluated before and 8 weeks after methotrexate therapy (in the peak of methotrexate effect). Results: No significant difference was found between the plasma profile of homocysteine, vitamin B12 and folate before and after methotrexate treatment. Conclusion: In the short-term treatment of psoriasis, methotrexate does not increase homocysteine level.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate.

Plasma homocysteine levels were determined in patients who participated in a randomized, double-blind placebo-controlled trial of folate supplementation (1 mg/day) during methotrexate therapy for rheumatoid arthritis. Plasma and red blood cell folate levels before methotrexate therapy were significantly negatively correlated with homocysteine levels. Homocysteine levels were not significantly c...

full text

Pulmonary function in patients receiving long-term low-dose methotrexate.

STUDY OBJECTIVE Acute interstitial pneumonitis is the main pulmonary side effect during methotrexate (MTX) treatment for rheumatoid arthritis. The aim of the study was to determine the following: (1) the incidence of MTX-induced pneumonitis during low-dose long-term MTX treatment for chronic arthritis; (2) whether periodic pulmonary function tests were useful for detecting MTX pneumonitis befor...

full text

Low dose Methotrexate for the treatment of generalized lichen planus

Background: Lichen planus is a common inflammatory disease that can involve the skin, nails, mucous membrane, and hair follicles. There is a long list of topical and systemic therapies for its treatment. Methotrexarte has some characteristics that make it a good choice for generalized lichen planus. Aim: The goal of this study was to assess the effect of low dose methotrexate in generalized lic...

full text

Acute and Long-Term Effects of High-Dose Methotrexate Treatment on Homocysteine in Plasma and Urine1

The amino acid, homocysteine, is not supplied by food but is a product formed by cleavage of S-adenosylhomocysteine; a productof transmetliylation. Homocysteine is further salvaged to methionine. Since this reaction is in most tissues dependent on 5-methyltetrahydrofolate, we investigated the effect of the antifolate drug, methotrexate (MIA), on homocysteine in patients treated with this drug a...

full text

Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine.

The amino acid, homocysteine, is not supplied by food but is a product formed by cleavage of S-adenosylhomocysteine; a product of transmethylation. Homocysteine is further salvaged to methionine. Since this reaction is in most tissues dependent on 5-methyltetrahydrofolate, we investigated the effect of the antifolate drug, methotrexate (MTX), on homocysteine in patients treated with this drug a...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 12  issue 1

pages  9- 12

publication date 2009-04-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023